- Home
- Pathology Industry
- Cancer Immunotherapy Market and Forecasts, May 2013
Industries
- Pathology (49)
- Drug and Medication (28)
- Biological Therapy (14)
- Biopharmaceutical (9)
- Genomics (7)
-
- Diagnostics (6)
- Energy & Environment (6)
- Biotechnology (5)
- Blood Supply, Tissue Banking and Transplantation (3)
- Pharmaceutical (3)
- Veterinary Healthcare (3)
- Advanced Material (2)
- Chemical and Material (2)
- Agriculture (1)
- Drug Delivery Technology (1)
- Drug Discovery and Development (1)
- Generic Drug (1)
- Medical Facility (1)
- Renewable Energy (1)
- Synthetic Material (1)
Top countries
Publication dates
All regions
data types
- All
- Company Data (508)
- Industry Data
- Country Data (16)
Cancer Immunotherapy Market and Forecasts, May 2013
You might be interested in: cancer therapy, stem cell, cell therapy, more »
industry reports
country reports
Biological Therapy Market Trends in The United States and Canada
- Industry report
- February 2013
- 9 pages
... That patient S breast cancer. Favorable implications for t-dm1 pricing. Based on management, we believe that roche may decide to be more aggressive on t-dm1 pricing than we currently assume. Looking at roche ...
- Industries: Biological Therapy
- Countries: United States, Canada
Biological Therapy Market Trends in The United States and Canada
- Industry report
- February 2013
- 9 pages
... For all of the roche oncology drugs used to treat that patient S breast cancer. Favorable implications for t-dm1 pricing. Based on management, we believe that roche may decide to be more aggressive ...
- Industries: Biological Therapy
- Countries: United States, Canada
U.S. Biological Therapy Business
- Industry report
- January 2013
- 49 pages
... R, tlr, chemokines, il-4r, il-7r, ras bcr, fcr, cd40, baff-r, tlr, integrins, chemokines targeted agents: redefining treatment goals Combination chemo- immunotherapy Chemo ...
- Industries: Biological Therapy
- Countries: United States
Cancer Market in The United States, Australia and Canada
- Industry report
- January 2012
- 13 pages
... To attack cancer cells and halt their out-of-control growth, as it has been shown to do with melanoma. - Rogress_in_cancer_immunotherapy ...
- Industries: Pathology
- Countries: United States, Australia, Canada
U.S. Prostate Cancer Sector Analysis (prostate cancer, urinary incontinence, breast cancer)
- Industry report
- February 2012
- 64 pages
... cancer typically have more rapid increase of psa over time compared to benign prostate disease summary Screening is effective in the right population Psa is an imperfect tool Age specific ...
- Industries: Pathology
- Countries: United States
Viral Vector Business Overview
- Industry report
- September 2011
- 35 pages
... C l i ni c a l s c orec l i ni c a l s c ore daily clinical scores after challenge infection with hpaiv h5n1. Developing personalized cancer vaccines for treating non- hodgkin S lymphoma ...
- Industries: Biological Therapy
U.S. Pharmaceutical Industry Analysis
- Industry report
- August 2011
- 80 pages
... Vaccine dendritic cell vaccine therapy represents a new and promising immunotherapeutic approach for treatment of advanced cancer as well as for prevention of cancer. The dendritic cell itself ...
- Industries: Pathology
- Countries: United States
U.S. Cancer Market : Innovation and Technology Trends
- Industry report
- January 2012
- 21 pages
... Mesothelioma Oral cancer Prostate cancer Skin cancer Celebrities and cancer as you go forward, please also remember: take it one day at a time. General cancer-surviving vet bikes cross ...
- Industries: Pathology
- Countries: United States
Cancer in The United States and Canada : Innovation and Technology Trends (ovarian cancer, prostate cancer)
- Industry report
- January 2011
- 17 pages
... Based vaccine, from merck kgaa Dpx-survivac vaccine disrupts survivin; re-activates apoptosis , enabling tumor cell death National cancer institute ranked survivin as top 25 promising cancer antigens ...
- Industries: Pathology
- Countries: United States, Canada
Cancer in Canada : Innovation and Technology Trends (ovarian cancer, prostate cancer, breast cancer)
- Industry report
- January 2011
- 17 pages
... Based vaccine, from merck kgaa Dpx-survivac vaccine disrupts survivin; re-activates apoptosis , enabling tumor cell death National cancer institute ranked survivin as top 25 promising cancer antigens ...
» Purchase Premium Reports (From $ 250 - $ 11 400)
46 reports for Cancer Immunotherapy
Small-Molecule Targeted Cancer Therapies: World Market 2013-2023
- $ 2 492
- Industry report
- December 2012
- by Visiongain
Report Details Cancer treatment with small molecules - your guide to trends and revenue prospects What does the future hold for small targeted agents to treat cancers? Visiongain's updated report gives ...
Reportlinker.com © Copyright 2013. All rights reserved.
